Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Priorities for developing respiratory syncytial virus vaccines in different target populations

Drysdale SB., Barr RS., Rollier CS., Green CA., Pollard AJ., Sande CJ.

About 38 candidate vaccines and monoclonal antibodies are in clinical development for treating respiratory syncytial virus in different populations.

Original publication

DOI

10.1126/scitranslmed.aax2466

Type

Journal article

Journal

Science Translational Medicine

Publisher

American Association for the Advancement of Science (AAAS)

Publication Date

18/03/2020

Volume

12